Research
Topics:
INDEX
AI-chat 3
PRIME 17
PRIO 1
aging 2
body 2
brain 6
cancer 5
climate 1
crime 3
culture 5
dental 1
diabetes 1
diagnostics 1
economy 1
energy 1
exercise 2
gender 1
genetics 1
heart 2
metabolism 2
misc
nutrition 3
pain 1
pollution 1
practice 2
psychology 1
religion 1
reproduction 1
unk
virus 1
war-confl
 
Scanned: 2617
Evaluated: 92
Selected: 33
 
    CANCER   

Mca05-024

Diagnostic Test Accuracy of Commercially Available Tests for The Recurrence of Bladder Cancer: A Systematic Review and Meta-Analysis

Quote:Conclusions This meta-analysis reveals that commercially UBTs for BC recurrence have varying diagnostic accuracy. Among the evaluated tests, Uromonitor demonstrated the highest pooled sensitivity and specificity, while Xpert Bladder Cancer and Bladder Epicheck showed reliable diagnostic performance. Further research is needed particularly for less extensively studied assays to establish their diagnostic performance.
Abstract: https://www.medrxiv.org/content/10.64898/2026.02.02.26344871v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.02.02.26344871v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Evangelia Ntzani Konstantina-Eleni Tsarapatsani Georgios-Alexandros Asimakopoulos Hawre Jalal Stella K Kang Thomas A Trikalinos span classnlm-collab data-hwp-idcollab-1CISNET Bladder Cancer Modeling Investigators, 
    CANCER   

Mca05-026

Frailty, initial attrition and the potential use of novel platinum-free options for non-small-cell lung cancer in the real-world setting

Quote:Conclusions The high initial attrition of approximately 25 in NSCLC could improve with availability of monoimmunotherapy, but requires optimized, faster patient workflows for better mitigation. Adoption of the SmPC criteria could support a priori identification of patients at risk for mBSC or platinum overtreatment to enhance utilization of monoimmunotherapy and other novel platinum-free first-line options in the future.
Abstract: https://www.medrxiv.org/content/10.64898/2026.02.02.26345340v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.02.02.26345340v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Petros Christopoulos Miriam Blasi Sandra Langer Shuo Shi Jelena Cvetkovic Farastuk Bozorgmehr Michael Allgaeuer Kadriya Yuskaeva Marc Schneider Rajiv Shah Jonas Kuon Albrecht Stenzinger Thomas Glueck Michael Thomas, 
    CANCER    REPRODUCTION   

Mep05-026

The Health Interventions Impact Calculator HIIC: scaling up web-based access to proportional multistate lifetable analyses of avoidable burden, health gain and economic impacts

Quote:We created a free online tool called the Health Interventions Impact Calculator that allows users to explore future scenarios for health interventions. Users enter details about a proposed intervention, such as reducing obesity, improving disease screening, or enhancing treatment, and the tool estimates future outcomes: deaths averted; health improvements, and costs over the next 10, 20, or 40 years. The tool compares each scenario against a business-as-usual future to show what additional benefits the intervention might achieve. We demonstrated this using three examples in Australia: a body-mass index intervention, a heart disease prevention intervention, and improvements to cervical cancer treatment. Currently available for Australia with over 200,000 ready-to-use scenarios and expanding worldwide in 2026
Abstract: https://www.medrxiv.org/content/10.64898/2026.02.01.26345324v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.02.01.26345324v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Stephanie Khuu Tim Wilson Bibha Dhungel Samantha Howe Tony Blakely, 
    CANCER   

Mge05-024

Routine germline genetic testing in 3552 unselected NHS breast cancer patients: Evidence informing testing criteria and implementation of a BRCA-DIRECT mainstreaming pathway

Quote:Conclusions Evidence from the NT-MBGT programme demonstrates that expanding BCSG-testing via a clinician-light pathway is acceptable and feasible, without increasing the burden on limited breast and genetics workforce, and has high satisfaction. Simplified testing criteria could improve identification of gPVs in HP-BCSGs. The concomitant increased pick-up of gPVs in IP-BCSGs warrants further consideration. highlights
Abstract: https://www.medrxiv.org/content/10.64898/2026.02.02.26344266v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.02.02.26344266v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Bethany Torr Lea Mansour Caitlin T Fierheller Monica Hamill Joshua Nolan Nicola Bell Subin Choi Sophie Allen Sudeekshna Muralidharan Suzanne MacMahon Yasmin Clinch Mikel Valganon-Petrizan Helena Harder Alice Garrett D. Gareth Evans Angela George Valerie Jenkins Lesley Fallowfield Rosa Legood Zoe Kemp Ranjit Manchanda Clare Turnbull, 
    AI-CHAT    CANCER   

Mpc05-022

Can ChatGPT give holistic and accurate patient-centered information to oncology patients? A mixed-methods evaluation with stakeholders

Quote:Conclusion This study highlights current challenges in using LLMs to explain complex cancer diagnoses and treatment records, including inaccurate information, inappropriate language, limited personalisation, AI distrust and challenges in integrating LLMs into clinical workflow. Understanding of the limitations is crucial for clinicians, patients, computer scientists and policy makers. The issues should be addressed before deploying LLMs in clinical settings.
Abstract: https://www.medrxiv.org/content/10.64898/2026.02.02.26345346v1
Full Text: https://www.medrxiv.org/content/10.64898/2026.02.02.26345346v1.full-text
Search Similar: Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho 
Search Authors: Mengxuan Sun Ehud Reiter Peter Murchie Anne E Kiltie George Ramsay Lisa Duncan Rosalind Adam, 

  Updated weekly. 02/06/2026-07:55:17 PM
Javilk's Research Links
Drop me a note to subscribe.
What interests you?